trending Market Intelligence /marketintelligence/en/news-insights/trending/lnCbS3Re1a2znvY5UrXrsQ2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Exelixis gets FDA expanded approval for kidney cancer drug

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Exelixis gets FDA expanded approval for kidney cancer drug

The U.S. Food and Drug Administration approved Exelixis Inc.'s Cabometyx tablets for the expanded indication of patients with advanced renal cell carcinoma.

Renal cell carcinoma is the most common form of kidney cancer in adults.

The expanded approval of the drug is based on results from a phase 2 trial in patients with previously untreated renal cell carcinoma, where the drug showed statistically significant and clinically meaningful improvement in progression-free survival versus current standard of care sunitinib.

Cabometyx, which the agency approved in April 2016 to treat advanced renal cell carcinoma in patients who have received prior anti-angiogenic therapy, demonstrated a 52% reduction in the rate of disease progression or death in the trial. Median progression-free survival for the drug was 8.6 months versus 5.3 months for sunitinib.

The FDA has previously granted priority review to the company's supplemental new drug application for Cabometyx.